Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This paper describes a traceability system developed for the Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology consortium. The system combines records and labels that to biological material across geographical locations and scientific processes from sample donation to induced pluripotent stem cell line. The labeling system uses a unique identification number to link every aliquot of sample at every stage of the reprogramming pathway back to the original donor. Only staff at the clinical recruitment site can reconnect the unique identification number to the identifying details of a specific donor. This ensures the system meets ethical and legal requirements for protecting privacy while allowing full traceability of biological material. The system can be adapted to other projects and for use with different primary sample types.

Original publication

DOI

10.2217/rme.15.66

Type

Journal article

Journal

Regen Med

Publication Date

01/2016

Volume

11

Pages

73 - 79

Keywords

biobanking, induced pluripotent stem cells, innovative medicines initiative, legal requirements, privacy, research collaboration, tissues and cells directive, traceability, Biological Assay, Drug Discovery, Humans, Induced Pluripotent Stem Cells, Stem Cell Research